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Background: Hormonal treatment might affect the immune response to tumor antigens induced in cancer
patients who are being vaccinated.
Case presentation: A 33 years-old woman was diagnosed with cutaneous melanoma in May 2009. Her melanoma
was located in the intermammary sulcus, had a Breslow thickness of 4 mm, a Clark’s level IV, it was ulcerated and
highly melanotic. The bilateral sentinel node biopsy was negative. She entered into a randomized Phase II/III clinical
study comparing a vaccine composed of irradiated melanoma cells plus BCG plus GM-CSF versus IFN-alpha 2b and
she was assigned to the vaccine arm. During the two years treatment she remained disease-free; the final CAT scan
being performed in August 2011. Between November and December 2011, her gynecologist treated her with three
cycles of 200 mg progesterone/day for ten days, every two weeks, for ovary dysfunction. In November 2011 the
patient returned to the Hospital for clinical and imaging evaluation and no evidence of disease was found. At the
next visit in March 2012 an ultrasound revealed multiple, large metastases in the liver. A CAT scan confirmed the
presence of liver, adrenal glands and spleen metastases. A needle biopsy of a liver lesion revealed metastatic
melanoma of similar characteristics to the original tumor. We suggest that progesterone treatment triggered
proliferation of so far dormant micrometastases that were controlled during CSF470 vaccine treatment.
Conclusion: The use of progesterone in patients with melanoma that are under immunological treatments should
be carefully considered, since progesterone could modify the balance of pro-inflammatory and Th1 functions to a
regulatory and anti-inflammatory profile of the immune system that could have an impact in tumor progression.
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The reports associating melanoma progression and pro-
gesterone (Pg) exposure during pregnancy or the use of
oral contraceptives have been controversial. Many au-
thors have reported a poor prognosis in pregnant wo-
men with melanoma as compared to non-pregnant
women’s tumor. Several retrospective reviews showed a
worsened prognosis in pregnant women with melanoma
and found that PgR and ER can be detected in melan-
oma tissue [1]. Instead, recent data found no increased
risk of CM with the use of exogenous female hormones
[2], and the timing of the disease diagnosis during* Correspondence: barrio.marcela@gmail.com
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reproduction in any medium, provided the orpregnancy did not appear to influence the risk of melan-
oma mortality [3]. However, significant associations of
CM with parity and age of first pregnancy were found,
thus warranting further research [2].
Given this scenario, hormonal treatment might affect
the immune response to tumor antigens induced in pa-
tients who are being vaccinated, but to our knowledge
this has not been previously reported.
In this report we present the case of a melanoma
patient treated with a melanoma vaccine [4,5] that
remained disease-free for two years but afterwards
showed a dramatic progression after receiving only one
month of Pg therapy for ovary dysfunction.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 33 years-old caucasian woman, nulliparous, presented
with a quick, suspicious growth of a congenital nevus
located in the intermammary sulcus and which was ul-
cerated. After surgery in May 2009 she was diagnosed
with stage IIC cutaneous epithelioid nodular melanoma,
in vertical growth phase, with a Breslow thickness
of 4.1 mm and a Clark’s level of IV. The tumor was
highly melanotic, ulcerated, and presented scarce
lymphocytic infiltration (Figure 1A). The bilateral senti-
nel lymphnode biopsy was negative. After giving written
consent she entered into a randomized Phase II/III clin-
ical study comparing the CSF470 vaccine plus BCG plus
GM-CSF versus IFN-alpha, and she was assigned to the
vaccine arm. The clinical study (CASVAC0401) has
been approved by the Comite Independiente de Etica
para Ensayos en Farmacología Clínica, “Profesor Luís
M. Zieher” Buenos Aires, Argentina. CSF470 vaccine
consists in a mixture of four gamma-irradiated melan-
oma cell lines injected i.d. plus 106 cfu BCG plus 400 μg
rhGM-CSF (divided in four daily injections, 100 μg
GM-CSF each). She started the clinical study two
months after surgery (July 2009) with a LDH = 287 U/L
(normal range 230–460). She received a total of 13
doses of CSF470 vaccine (the first 4 doses, every three
weeks, then every two months until completion of the
first year and finally every 3 months in the second year)
with good tolerance presenting only grade 2 toxicity
(erythema, edema and pain) at the vaccination site.
DTH reactions were quite strong and lasted at least
three days after vaccination (Figure 1B). During the
course of the study, a cervical lymph node suspiciously
enlarged, but then returned to normality and no biopsy
was performed.
In June 2010, a control CAT scan depicted an ovarian
cyst that suggested a functional cyst or endometriosis. In
August 2011 she completed the clinical study of CSF470
vaccine and she was found to be disease-free by CAT scans
of the brain, abdomen, thorax and pelvis (Figure 1C-D).
Her serum LDH was 309 U/L, and the patient returned to
her hometown.
Between November and December 2011 she was
treated by her gynecologist with three cycles of Pg,
200 mg/day for ten days, every two weeks (MAFEL,
Raymos Laboratories, Argentina), to treat her ovarian
cyst. At that time (November 2011) her serum LDH was
369 U/L and all other blood laboratory values were nor-
mal. Chest radiography was normal and abdominal
ultrasound only showed a 4 cm diameter ovarian cyst,
without adenopaties. No CAT scan was made at that
time. In March 19/2012 the patient came to a new
follow-up visit and ultrasound showed multiple liver het-
erogeneous diffuse nodules (20-25 mm) that were fur-
ther confirmed by CAT scan, along with expansivelesions in both suprarenal glands and a spleen nodule
(Figure 1E-F). Her serum LDH value was 767 U/L. A
fine needle biopsy of a liver nodule confirmed the pres-
ence of melanoma metastasis, with highly melanotic
cells (Figure 1G). The patient was treated with two cy-
cles of biochemotherapy [6] plus tamoxifen with no clin-
ical response. Within the next two months the patient
developed brain metastases, detected by MNR, and sub-
cutaneous nodules in the neck. BRAF sequencing of the
liver biopsy revealed the presence of V600E mutation
and the patient started Vemurafenib treatment (960 mg
b.i.d) in July 2012, attaining partial remission.
Lack of hormone receptors (ER and PgR) was found in
the primary tumor biopsy by immunohistochemistry
(Figure 1H and I), but this finding could not be con-
firmed in the hepatic metastasis biopsy due to lack of
material.
Discussion
It is well known that reproductive steroid hormones,
particularly Pg, in addition to its widely recognized ef-
fects on endometrial epithelial and stromal cells and
spiral arteries, affect the activity of the immune system,
inducing active immune tolerance against fetal antigens
during pregnancy [7]. The immune-modulatory effects
of Pg involve a number of immune effectors, i.e., it
blocks mitogen stimulated T cell proliferation [8], it in-
creases secretion of IL-10 by T cell clones [9], it modu-
lates antibody production [10], it decreases the oxidative
burst of monocytes [7], and it reduces pro-inflammatory
cytokines production by macrophages in response to
bacterial products [9]. Pg alters the balance of Th1/Th2
immune profiles towards Th2, inducing IL4, IL5 and
IL10 production [9]. Also, IFN-related genes are down-
regulated in peripheral blood lymphocytes in women’s
luteal phase, when Pg reaches peak levels, as compared
to the follicular phase of the cycle [11].
The link between Pg and the immune system is
established by lymphocyte Pg receptors expressed in per-
ipheral blood gamma-delta T cells of pregnant women
and in peripheral NK cells. Regulation of lymphocyte Pg
receptors is dependent on T cell activation, since effi-
cient recognition of fetal antigens is a requirement for
the initiation of Pg-dependent immune-regulatory mech-
anisms [12]. Also, it has been shown that during preg-
nancy, the severity of diseases caused by inflammatory
responses (i.e. multiple sclerosis) is reduced and the se-
verity of diseases that are mitigated by inflammatory
responses (i.e. infections like influenza and HPV) is in-
creased [13].
Regulation of host immune system by Pg-based con-
traceptives treatment of animals and humans can have
significant effects on the host immune response. Pg can
modulate both the innate and adaptive immune system,
Figure 1 Pictures of 001-CSS patient melanoma and CAT scans. A- Micrograph of the primary tumor (hematoxylin/eosin staining) showing
highly melanotic tumor cells and scarce lymphocytes in the tumor periphery. Original magnification = 200×; scale bar = 20 μm. B- DTH reaction
to the vaccine at the right forearm is shown as an example of patient’s immune reaction after receiving eight doses of CSF470 vaccine plus BCG
plus GM-CSF, as described in the text. C and D- CAT scan pictures of the abdomen obtained by the end of the clinical study (August 2011). No
melanoma lesions were detected. E and F- CAT scan pictures obtained at March 2012, three months after the patient received Pg treatment,
showing multiple lesions in the liver, suprarenal glands and spleen. G- Micrograph of a hepatic needle biopsy (hematoxylin/eosin staining)
confirming the presence of multiple melanoma metastases in the hepatic parenchyma. Original magnification = 200×; scale bar = 20 μm.
H- Immunohistochemical staining for PgR in the primary tumor was negative; I- positive control for PgR staining (breast carcinoma). For both,
original magnification = 400×; scale bar = 10 μm.
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viral infections, like HPV or HIV. It has been previously
reported that mice treated with depot medroxy-
progesterone acetate (DMPA) have decreased levels of
HSV-2 specific mucosal immune responses after
intravaginal immunization with the attenuated strain of
HSV-2 (TK-HSV-2). Consequently, these mice fail to
develop protective immune responses against subse-
quent WT HSV-2 challenge [14]. A more recent study
reported that Pg treatment at concentrations achieved
during hormone-therapy, decreases the proliferation
and Th1-type cytokine production of varicella-zoster
virus-specific CD8+ and CD4+ T cells, and this effect
was exacerbated in cells obtained from HIV-infected in-
dividuals [15]. Since Pg decreases antibody production,
CTL activity, IFN-gamma production, and antibody-
dependent cell cytotoxicity activity in women using
Pg-based contraceptives, these facts may contribute to
the increased susceptibility and shedding of HIV-1 ob-
served in women using these hormone therapies [16].
Similarly, Pg could negatively influence specific Th1 and
pro-inflammatory immune responses induced by active
immunization with tumor vaccines.
In view of the results presented, we hypothesize that
as a consequence of CSF470 vaccination, the patient’s
melanoma remained under control of the immune sys-
tem for two years, although her tumor was possibly dis-
seminated as micrometastases below the detection level
of CAT scans. Three months after completing Pg treat-
ment for her ovary cysts a rapid disease progression en-
sued. A possible explanation could be that Pg treatment
decreased the activity of immune effectors elicited by
the anti-melanoma vaccine and/or increased the func-
tion of regulatory T cells, thus unbalancing the patient’s
immune system. Since her primary CM showed no PgR
expression, a direct mitogenic role of Pg on melanoma
cells seems less probable, although we cannot rule out
that the metastases could have expressed PgR, since we
could not address this point due to scarce material from
the liver biopsy.
Conclusion
We believe that this case brings a word of caution to be
considered when cancer immunotherapy is combined or
concomitantly administered with hormone therapy, evi-
dencing the delicate interactions established between the
immune responses elicited by vaccines, the immune-
modulating effect of sex hormones and tumor cells.
Consent
Written consent for publication of her clinical details
and/or clinical images was obtained from the patient. A
copy of the consent form is available for review by the
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